Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

161 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to investigate the effect of various modified low volume polyethylene glycol (PEG) 3350 and ascorbic acid/ascorbate (PEG+ASC)-based gut cleansing solutions on stool output in healthy subjects. In addition, the study is to assess and compare the safety and tolerance of the modified PEG+ASC formulations following oral administration with the safety profile of MOVIPREP®.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy

NCT01714466

Colon Cancer

COMPLETED PHASE2

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

NCT02273167

Colorectal Cancer Colorectal Carcinoma Colon Cleansing

COMPLETED PHASE3

A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution

NCT00389233

Colonoscopy

COMPLETED PHASE3

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.

NCT02273141

Colorectal Cancer Colorectal Carcinoma Colon Cleansing

COMPLETED PHASE3

Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to Colonoscopies

NCT01251237

Colon Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A, arm 1

Evening dose 1 plus fixed morning dose

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Part A, arm 2

Evening dose 2 plus fixed morninf does

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Part A, arm 3

Evening dose 3 plus fixed morning dose

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Part A, arm 4

Moviprep

Group Type ACTIVE_COMPARATOR

Moviprep

Intervention Type DRUG

Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.

Part B, arm 1

Fixed evening dose plus morning dose 1

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.

Part B, arm 2

Fixed evening dose plus morning dose 2

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.

Part B, arm 3

Fixed evening dose plus morning dose 3

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.

Part B, arm 4

Fixed evening dose plus alternative morning dose

Group Type EXPERIMENTAL

NER1006

Intervention Type DRUG

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NER1006

Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Intervention Type DRUG

NER1006

Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Intervention Type DRUG

NER1006

Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.

Intervention Type DRUG

Moviprep

Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.

Intervention Type DRUG

NER1006

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.

Intervention Type DRUG

NER1006

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.

Intervention Type DRUG

NER1006

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.

Intervention Type DRUG

NER1006

Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject's written informed consent must be obtained prior to inclusion.
2. Healthy subjects with an age of 18 to 45 years.
3. Healthy subjects need to be without any history of clinical significant gastrointestinal symptoms by clinical judgement and without the presence of acute abdominal discomfort or symptoms.
4. Females must be surgically sterile, practicing true sexual abstinence or using an acceptable form of effective contraception throughout the study from the following list: contraceptive implants, injectables, oral contraceptives, intrauterine system (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository. Hormonal and IUD methods of contraception must be established for a period of 3 months prior to dosing and cannot be changed or altered during the study. All females must have a negative pregnancy test at screening and check-in.
5. Willing, able and competent to complete the entire procedure and to comply with study instructions.

Exclusion Criteria

1. Use of laxatives in the last 12 months or colon motility altering drugs in the last 6 months.
2. Use of any prescription or over-the-counter (OTC) medication within 4 weeks prior to the first dose of investigational drug (excluding hormonal contraception, and occasional use of nonsteroidal anti-inflammatory drugs \[NSAID\], acetaminophen or metamizole).
3. Donation or loss of 500 mL or more of blood within 8 weeks prior to the first dose of investigational drug.
4. Any evidence of the history or presence of organic or functional gastrointestinal conditions (e.g. chronic constipation, irritable bowel syndrome \[IBS\], inflammatory bowel disease \[IBD\]).
5. Exhibiting relevant abnormal gastrointestinal motility according to clinical judgement in the past or now.
6. History or presence of any clinically significant acute illness within the 4 weeks prior to the first dose of investigational drug based on clinical judgement at screening and check-in evaluation.
7. Known glucose-6-phosphatase dehydrogenase deficiency.
8. Known phenylketonuria.
9. History or evidence of any clinical significant systemic cardiovascular, hepatic, pulmonal, neurological, metabolic and/or renal organ dysfunction.
10. History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis), known hypersensitivity to polyethylene glycols and/or ascorbic acid.
11. History or evidence of any clinically relevant electrocardiogram (ECG) abnormalities and hypertension.
12. Evidence of dehydration.
13. Any evidence for abnormal sodium or potassium levels or clinically significant other electrolyte disturbances.
14. Females who are pregnant, having a positive pregnancy test at screening and/or admission to unit or planning a pregnancy. Females not using reliable methods of birth control.
15. Clinically relevant findings on physical examination based on Investigator's judgement.
16. Clinically relevant deviations of laboratory parameters from reference ranges at screening or check-in evaluation.
17. Positive serology for chronic viral hepatitis or human immunodeficiency virus (HIV) at screening.
18. History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or check-in evaluations.
19. Subjects who are unwilling to comply with the provisions of the study protocol.
20. Concurrent participation in an investigational drug study or participation within 3 month of study entry.
21. Subject has a condition or is in a situation, which in the Investigators opinion may put the subject at significant risk, may confound the study results, or may interfere significantly.
22. Previous participation in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes